February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
January 2015 in “Journal of cosmetics, dermatological sciences and applications” The combined technology safely and effectively removes hair at home on dark skin.
January 2009 in “Side effects of drugs annual” Some blood-thinning medications can increase the risk of bleeding, and certain factors like genetics and other health conditions affect their safety and effectiveness.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
May 2026 in “Frontiers in Immunology” Bimekizumab effectively treats scalp cellulitis and improves quality of life.
May 2026 in “Skin Appendage Disorders” Lasers and energy-based devices effectively and safely treat hair loss, especially when combined with other treatments.
Lasers and energy-based devices effectively and safely improve hair growth in androgenetic alopecia, especially when combined with other treatments.
Lasers and energy-based devices effectively and safely improve hair growth in androgenetic alopecia, especially when combined with other treatments.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Xtressé™ gummies are safe and may help improve hair in women with non-scarring hair loss.
May 2026 in “SKIN The Journal of Cutaneous Medicine” The supplement gummy and serum safely improve hair growth in women with hair loss.
May 2026 in “Rowan Digitals Works (Rowan University)” Adding oral probiotics to standard acne treatments improves results and reduces side effects.
Biotin supplements don't consistently help hair growth in alopecia unless there's a deficiency.
May 2026 in “Journal of the American Academy of Dermatology” Sublingual minoxidil safely increases hair growth in transgender people on testosterone therapy.
May 2026 in “Journal of Cosmetic Dermatology” Fractional laser therapy effectively and safely improves hair density in androgenetic alopecia.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
April 2026 in “Frontiers in Medicine” The 675-nm diode laser may safely help treat telogen effluvium.
April 2026 in “International Journal of Research in Dermatology” Laser therapies may improve scarring alopecia, but more research is needed.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
April 2026 in “Stem Cell Research & Therapy” Regenerative treatments improve hair growth in androgenetic alopecia with mild side effects.
April 2026 in “Clinical and Experimental Dermatology” Dupilumab effectively reduces symptoms of prurigo nodularis and is safe for long-term use.
March 2026 in “Journal of Cosmetic Dermatology” Topical Stemoxydine improves hair density in androgenetic alopecia with few side effects.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
March 2026 in “Food, Nutrition and Health.” Collagen peptides may help reduce skin aging by improving elasticity and hydration.
PRP may help with female hair loss short-term, but more research is needed for best results.
Topical latanoprost acid at 0.05% concentration improved hair growth in women with androgenetic alopecia.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
March 2026 in “Journal of Dermatological Treatment” Topical 3% minoxidil effectively and safely enhances facial hair in transgender men.